Tuesday, 17 November 2020

BioLargo's water technologies closer to commercialization, reports record 3Q

Source: Proactive Investors (https://ca.proactiveinvestors.com/companies/news/934217/biolargo-s-water-technologies-closer-to-commercialization-reports-record-3q-934217.html 



BioLargo, Inc (OTCQB:BLGO) CEO Dennis Calvert tells Proactive its 3Q financial results saw its revenue rise 26% year-over-year to a record $0.67 million. Calvert says the group is ramping up several of its water technologies to prepare for commercialization including the AOS and the AEC, which he says will lead to first sales.

What's more, its industrial operating divisions each have a backlog of revenue-generating projects that collectively exceed $2 million, which it says will provide “reliable revenue” into 2021.

Monday, 16 November 2020

BioLargo Revenue Continues Breaking Records as Water Technologies Ready for Commercialization

Technology Portfolio Expanding

Westminster, CA – November 16, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, filed with the SEC its Quarterly Report on Form 10-Q for the period ended September 30, 2020 (www.biolargo.com/sec-filings).

BioLargo’s Third Quarter Accomplishments

  • Record revenue – generated record revenues in the third quarter, rebounding from early pandemic shutdowns
  • New business backlog – BioLargo’s industrial operating divisions each have a backlog of revenue-generating projects that collectively exceed $2 million, providing reliable revenue into 2021
  • Advanced PFAS (“forever chemicals”) removal technology – Refined the AEC water treatment technology, developed a modular AEC unit, and have entered into substantial negotiations with a major municipal water agency regarding a pilot project
  • New CupriDyne formula – developed a new CupriDyne formula and are preparing an application to register a product as a sanitizer and hard-surface disinfectant with the US EPA
  • Launched COVID product – our medical subsidiary launched Clyraguard Personal Protective Spray on Amazon, and expanded sales of Clyraguard from first quarter; it is launching a new product soon, with another expected in mid to late 2021
  • Developed a new technology – BioLargo engineers invented a way to extract valuable minerals from certain types of industrial waste, turning a customer’s liability into a billion-dollar revenue opportunity while also creating a long-term revenue opportunity for BioLargo’s engineering team
  • Sales of odor and VOC control solutions to Cannabis operators expanding – CupriDyne Clean odor control product’s use is expanding in the Cannabis industry
  • Municipal wastewater pilot under way – began construction of a commercial-scale AOS water treatment system for delivery to a municipal wastewater treatment plant in Montreal, Canada
  • Improved balance sheet – retired over $3.5 million in debt (by converting to equity), leaving approximately $1.1 million due in August of 2021 or later, and the remaining paid by Clyra subsidiary from sales or as funds are available from financing efforts

BioLargo President and CEO Dennis P. Calvert commented, “Several of our patented technologies are on the cusp of significant commercial breakout. Our two water technologies – the AOS and the AEC – are now ready for commercial trials that we believe will lead to first sales. We are constructing our first commercial ready AOS unit now. At the same time, we are refining comprehensive marketing plans for their rollout and are already in discussions with customers, distributors and strategic partners.”
















The company has continually advanced its robust portfolio of technologies since it started this journey in the spring of 2007. The technology portfolio has expanded to include:

  • PFAS removal
  • SARS-CoV-2 solutions
  • Infection control
  • Wound management
  • Regenerative tissue therapy
  • Disinfection
  • Air quality controls and systems including odor and VOC control
  • Water decontamination
  • Micro-pollutant destruction and removal
  • Legionella detection and water treatment solutions
  • Minerals processing

Calvert continued, “We have assembled world-class technologies and talent and are focused on their highest and best purpose. While extraordinarily difficult, we have consistently invested in R&D while advancing from technology to product and onto first commercial sales and bundled services. We are now witnessing the first stages of disruption, proving their opportunities for significant commercial futures. We believe the value of our technology portfolio is far greater than is currently reflected in our stock price and continue to march forward knowing that the portfolio has a future that will generate value for decades to come. The innovator’s journey is never easy, and there is no doubt that the pandemic presented real additional challenges for BioLargo, but we are now in a position where our balance sheet has dramatically improved, our revenues are rebounding, and we have several potentially disruptive technologies ready to launch into the marketplace. I was reminded recently by a highly trained and accomplished innovator that, ‘solutions to some of the most important challenges in the world LIVE at BioLargo’.  We agree and know it’s only a matter of time before we see their dramatic impact around the world for a greater good.”

 

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

During the course of the stockholder presentation, BioLargo may make “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding future events or the future financial performance of the company that are subject to change. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

 

Monday, 2 November 2020

Clyraguard Highlighted in Rolling Stone and Men's Journal

BioLargo and its subsidiary Clyra Medical Technologies are rolling out Clyraguard around the country, and it's starting to turn some heads. Now that the product is available on the company's website and on Amazon, the timing is perfect.

Last week, two articles were published about Clyraguard that do a great job capturing the value of this product. First, a Rolling Stone article highlighted how Clyraguard can help improve mask-wearing practices to help keep people safe. Second, a Men's Journal article reviewed the product from a broader perspective.

You can get to these articles right here:

If you are a follower of BioLargo or Clyra, we'd love to hear your thoughts about the new product. Make sure to follow us on social media - you can find us at:

Tuesday, 27 October 2020

Odin (BioLargo/BKT Joint Venture) Headquarters Moving to Korea Water Cluster in Daegu, South Korea

Earlier this year, BioLargo announced the formation of a joint venture with BKT & Tomorrow Water to launch BioLargo’s patented odor and VOC control product CupriDyne Clean (www.cupridyne.com) into the Asian market under the brand name “Odin”. The new join venture was designed to manufacture and support distribution of the odor and VOC control products developed and sold by its subsidiary ONM Environmental, Inc. (www.onmenvironmental.com) in multiple countries throughout Asia, focusing initially on BKT’s established water and wastewater customer base.

BKT is a leading wastewater treatment solutions provider operating in the USA, South Korea, and Vietnam with a reputation for adopting innovative, environmentally sustainable technologies and practices. In the agreement between BioLargo and BKT, it was planned that the joint venture would eventually move its headquarters to the city of Daegu, which is a center for high-tech innovation in South Korea.

The BKT/BioLargo joint venture (Odin) is now officially moving its headquarters to the Korea Water Cluster in Daegu. The Korea Water Cluster is a newly opened water innovation hub in Daegu that provides significant business, scientific, engineering, human resources, and logistical assets to companies. Odin is set to be the first international joint venture headquartered at the Korea Water Cluster campus.

Water clusters and innovations groups exist all over the world, but the Korea Water Cluster is unique because of its significant physical footprint in Daegu, its substantial physical resources, and the funding it has received from the South Korean government. The Korea Water Cluster’s campus spans over 14 square kilometers, with state-of-the art testing facilities and business support centers.

Overview of Korea Water Cluster facilities (source: www.watercluster.or.kr


James Kim, COO of BKT, commented on the importance of the move to Daegu, “the Water Cluster will be a hub for R&D in the water  industry, and it will introduce innovative technologies in one place, providing opportunity for collaboration and cooperation among companies and ventures.”

He continued, “Korea Water Cluster will be a test bed and showcase for many innovative technologies not only for Korean clients but also many other clients in Asia. Odor is one of the major issues that wastewater treatment plants would like to remove, and it is becoming more important. By moving its headquarters to this Water Cluster, Odin will be naturally exposed to more clientele in Korea and also in Asia. BioLargo and Tomorrow Water signed an MOU with the City of Daegu at the WEFTEC last year, and the Mayor of Daegu promised strong support on market expansion in this region. Odin is the first foreign invested joint venture who moved into this cluster.”

Odin’s move to the Korea Water Cluster comes at a time when the joint venture is working to establish its manufacturing base for odor and VOC control products in South Korea. Not only will the move provide access for Odin to key opinion leaders in the water innovation industry in South Korea, but it will allow for significant business-to-business collaboration as the joint venture partners works to market Odin products in the region.

Wednesday, 21 October 2020

BioLargo Awarded Contract for Engineering Services at Major Chemical Manufacturing Facility

Westminster, CA – October 21, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, announced today that its subsidiary BioLargo Engineering, Science & Technologies (BLEST) has been awarded a contract to assist in the reconfiguration of the Regenerative Thermal Oxidizer (RTO) systems used at a large chemical manufacturing plant on the East Coast of the US, owned by a global chemical company, that produces phenolic resins, antioxidants and related synthetic organic products. The contract is expected to execute with a series of milestones through mid-2021, with anticipated scope expanding the contract period to at least 24 months and over $500,000 in total revenue.

A Regenerative Thermal Oxidizer is a device that destroys unwanted organic air contaminants produced as a result of the phenolic resin production process. An RTO is a highly energy-efficient technology that uses waste heat to eliminate organic air contaminants, and is a crucial piece of equipment for this chemical plant.

The plant is preparing to shut down an existing, older RTO and re-route the exhaust treated by that RTO to a newer, much larger and more efficient RTO. This will result in significant energy efficiency and cost savings improvements to the facility. The work to reconfigure these RTO systems is not trivial, requiring substantial engineering and design work to ensure it proceeds safely and efficiently. BLEST has been contracted to conduct the initial engineering work to assess the feasibility of the RTO reconfiguration project. BLEST engineers have significant experience engineering and designing RTO systems, with some of its engineers having designed multiple RTO systems for the facility.

 

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

During the course of the stockholder presentation, BioLargo may make “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding future events or the future financial performance of the company that are subject to change. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Thursday, 15 October 2020

Lorianne Shultz Awarded 2020 NWRI-BioLargo Graduate Fellowship

For many years, BioLargo has sponsored fellowships offered by the National Water Research Institute (NWRI) to graduate students in the US who focus on cutting-edge water research. This $5,000 fellowship recognizes students who research the technical and scientific aspects of advanced water and wastewater treatment.

This year, we are happy to announce that the NWRI-BioLargo Graduate Fellowship has been awarded to Lorianne Shultz, a PhD student at the University of Central Florida. Shultz’s research project, which she is completing in the laboratory of Dr. Titel Jurca, is called “Chlorine Stable Heterogeneous Catalysts for the Remediation of Stubborn Water Pollutants”.

Lorianne Shultz, NWRI-
BioLargo Fellowship winner

Lorianne explained to us the importance of her research, “Pharmaceuticals and personal care products are accumulating in our waterways at alarming rates; this is especially true with the world’s growing population. This issue can be remediated through heterogenous catalytic degradation of these pollutants, a methodology that I believe is commonly overlooked in the water-industry. I was thrilled to receive this fellowship as it helps validate the use of catalytic materials for water-remediation and these funds help me expand this field of research further. I am excited to be working in connection with BioLargo, a company so dedicated to this field and at the forefront of improvement for water treatment systems.”

Dennis P. Calvert, President & CEO of BioLargo, commented, “Shultz’s research goals align well with NWRI’s mission to protect and improve water management in the US, and they also align with BioLargo’s vision of seeking innovative new methods of addressing tough contaminants that threaten the health and safety of people around the world. We are thrilled to sponsor her work, and we are excited to learn from her research.”

NWRI is a 501c3 nonprofit that collaborates with water utilities, regulators, and researchers in innovative ways to help develop new, healthy sources of drinking water. To learn more about NWRI’s graduate fellowship program, go to the NWRI website: https://www.nwri-usa.org/fellowships.

Wednesday, 14 October 2020

Clyraguard Personal Protection Spray Now Available On Amazon.Com For Consumers Nationwide

BioLargo subsidiary Clyra Medical Technologies Joins Forces with Powerplay Retail to Ensure

Broad Availability of Revolutionary Product to Safeguard Against Airborne Viruses

Westminster, CA – October 14, 2020 – Just in time for Amazon Prime Day, BioLargo, Inc. (OTCQB:BLGO), developer of sustainable life science technologies, today announced that Clyraguard, the personal disinfectant and germicidal spray that safely and easily decontaminates masks and face coverings, is now available at the Clyra Medical Store on Amazon.com. Clyraguard is manufactured by BioLargo’s subsidiary Clyra Medical Technologies, a med-tech company with deep experience fighting hospital-acquired infections with innovative technologies.

In addition, Clyra Medical announced a partnership with Powerplay Retail, an agency and distributor that has helped launch some of the best-known consumer products in the world, to roll-out Clyraguard to major retailers nationwide. Powerplay Retail brings to bear relationships with some of the world’s biggest online and in-store retailers, including more than 80 of the largest, most recognizable retailers in the United States.

BioLargo President & CEO Dennis Calvert commented, “We have assembled an exceptional team to execute a multi-phase roll out plan for Clyraguard. This Amazon launch, in partnership with Powerplay Retail, is another important step toward maximizing consumer access to this valuable product.”

“As we continue to battle this unprecedented pandemic, Clyraguard provides an embedded layer of iodine on one’s mask or face covering for additional protection against unwanted pathogens, including the SARS-CoV-2 virus, without having to remove your mask,” said Steve Harrison, CEO, Clyra Medical Technologies. “Until now, this hospital-grade disinfectant was available only to healthcare professionals. Making Clyraguard available on Amazon.com, as well as partnering with Powerplay Retail, ensures we can deliver a much-needed solution to consumers nationwide.”

Clyraguard has shown complete inactivation of SARS-CoV-2 (COVID-19), according to recent testing at University of Texas Medical Branch at Galveston, and is based on Clyra Medical’s original advanced wound care technology, which received 510(k) clearance from the Food and Drug Administration (FDA).  Clyraguard is a hospital-grade, FDA-registered disinfectant that is specifically indicated for PPE, like masks and face coverings.

“At Powerplay our goal is to help our retail partners find the right brands and the right technologies while weeding out the noise in this increasingly competitive marketspace,” said Tracy Thie, Principal, Co-Founder Powerplay Retail.  “As health and safety have become a core part of our daily lives, we have made it a point to help support our retail partners to bring the right health & wellness products to the masses. Our partnership with Clyra creates a great opportunity to bring Clyraguard to market at a time when people want and need this product.”

Clyraguard has been rigorously tested and proven to be safe and long-lasting, providing an extremely high 99.999% antimicrobial efficacy against viruses, bacteria and fungi.  Gentle and safe, its eco-friendly ingredients are mineral-based, alcohol-free, non-toxic, non-irritating and non-sensitizing.

Available in 4 oz. spray bottle, the personal protection spray is small enough for a purse or pocket yet contains two months of supply with typical usage, and for travelers, Clyraguard classifies under current TSA hand sanitizer exemptions. Clyraguard is now available to consumers online at www.clyramedical.com, the Clyra Medical Store on Amazon.com, and soon to be available at retailers nationwide.

 

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About Clyra Medical Technologies

Clyra Medical Technologies, is a subsidiary of BioLargo, Inc. (OTCQB:BLGO), a sustainable science, technology and full-service environmental engineering company that makes life better by delivering world-class products and services across a broad range of industries, with a drive to deliver solutions in clean water and wastewater treatment, clean air and air quality control, and advanced antimicrobials for healthcare. 

About Powerplay Retail

Powerplay Retail is a privately held, Minnesota based company with offices in Bentonville, Arkansas, and Shenzhen China. With over 250 years of combined retail experience bringing brands like Beats by Dr. Dre and GoPro to consumers they continue to vet and identify new retail opportunities to best serve their brand and retail partners. For more information on Powerplay Retail, visit powerplayretail.com.

Contact

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

 

Thursday, 8 October 2020

BioLargo Breaks Revenue Records in Third Quarter of 2020

Clyraguard manufacturing and distribution through national partners begins

Westminster, CA – October 8, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and full-service environmental engineering company, today provided highlights of its results and activities from the third quarter of 2020.

BioLargo President & CEO Dennis P. Calvert commented, “With our subsidiary Clyra Medical Technologies having successfully executed the first phase of the Clyraguard product launch, this quarter set new records for BioLargo, and we expect the next quarter to be even stronger for the company and Clyraguard. We have made a significant investment in building our supply chain capabilities, organizing our marketing team, and dedicated business development efforts, and we expect future periods to continue to improve.”  

Financial highlights:

·       BioLargo achieved record company-wide revenue. Revenues for the period ended September 30, 2020 were approximately $650,000, representing about a 60% increase compared to the $418,000 generated in the second quarter of 2020.  Revenues for the nine months ended September 30, 2020 were approximately $1,600,000, about a 20% increase compared to the $1,324,000 generated in the nine months ended September 30, 2019.

·       Substantial improvements to the company’s balance sheet, with $3,553,000 of debt being converted to equity by the company since December 31, 2019.

Highlights for BioLargo’s subsidiaries:

Clyra Medical Technologies

·       Clyra is executing on its comprehensive roll out plan for Clyraguard Personal Protective Spray, having overcome early challenges developing a robust manufacturing and supply chain during Covid. New manufacturing relationships support capacity of up to 1,000,000 Clyraguard units per month, and ample supply has been placed with distributors across the country.

·       Sales channels launching now include the largest distributors to the healthcare and restaurant industries, Amazon.com, a revamped Clyraguard website (www.Clyraguard.com), and multiple online resellers, with a retail unit price of $25 per bottle.

·       The Clyraguard launch is supported by new company additions – Shawn Dougherty (Mophie founder), Johnny Sirpilla (former President of Camping World), and new agreements with a national marketing and public relations firm, and national sales organization, to be announced soon.

BioLargo Engineering, Science & Technologies

·       Multiple projects are being finalized with two major municipal public water agencies for the company’s PFAS treatment technology (the BioLargo AEC).

·       Developed a proprietary and patent-pending process to extract valuable mineral resources from a large industrial waste site. As a consequence of this new process, a client is planning a substantial long-term project expected to generate over $1B in revenues for the project. As the client’s engineering services provider, and developer of the technology, BioLargo Engineering is in discussions with the client to secure its role as the project manager and/or lead engineer.

·       Secured a client contract for a project to use regenerative thermal oxidation for air quality control (a particular expertise of some of our engineers), which is expected to generate $500,000 in revenue for BioLargo Engineering through 2021.  

·       BioLargo Engineering now has contracts in place for approximately $1,000,000 in revenue, which is expected to be realized between now through the end of 2021.

ONM Environmental

·       Revenues in the third quarter of 2020 began to rebound from their pandemic-related dip to approximately $350,000.

·       With nearly $400,000 in construction business already secured for the fourth quarter of 2020,  management expects the fourth quarter 2020 to be a new high record for revenue at ONM Environmental.

·       Cannabusters (ONM Environmental’s white label partner for the cannabis industry) is gaining traction in the market, resulting in 12 equipment installations for ONM Environmental so far, with another three contracted for the fourth quarter 2020.

BioLargo Water

·       BioLargo Water’s first commercial project for its AOS water treatment technology, wherein the first for-profit installation of an AOS will take place at a poultry farm, is moving forward as planned, and which is expected to generate more than $500,000 in revenue over the next year.

·       Our engineers are building the AOS unit to be installed at the wastewater treatment facility near Montreal, Quebec, for the demonstration pilot to be run in partnership with acclaimed water experts at the Centre des Technologies de L’Eau (CTE).

·       BioLargo Water secured Health Canada approval for two hand sanitizer product formulations and a license to manufacture and sell these products (one of which incorporates CupriDyne technology), to serve its local community.  

·       Developed and executed crucial EPA-approved protocols to produce data to support the efficacy of a CupriDyne technology-related disinfectant in preparation for an EPA application for a hard-surface disinfectant and sanitizer, in support of BioLargo’s efforts to secure EPA registration.

 

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard (www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

During the course of the stockholder presentation, BioLargo may make “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding future events or the future financial performance of the company that are subject to change. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Sunday, 20 September 2020

BioLargo Wins Octane HTA Award for COVID-19 Response

Over the past few months, BioLargo pivoted to develop and deliver solutions to help combat the COVID-19 pandemic, including Clyraguard Personal Protection Spray, manufactured and sold by our subsidiary Clyra Medical Technologies. At the outset of the pandemic, we recognized that our iodine-based technologies would make a meaningful contribution to the fight against SARS-CoV-2 (the virus that causes COVID-19). Our response is directly in line with our mission statement to “make life better” because nothing is more important right now than helping protect people against this virus.

Last week at the 27th Octane High Tech Awards, BioLargo was honored for its contribution to the fight against COVID with a “COVID-19 Response Recognition Award”. We thank the Octane team for this honor, and we are humbled to have been recognized among such incredible Orange County based innovators.

The award highlighted BioLargo’s agile response to COVID. They noted that the company’s subsidiary Clyra Medical Technologies worked quickly to roll out Clyraguard Personal Protection Spray (www.clyramedical.com/clyraguard), which recently launched to great enthusiasm, with sales and distribution presently ramping up through national partners.

Clyraguard, an FDA-registered hospital-grade disinfectant, offers an additional line of defense against COVID-19. It helps protects mask-wearers from cross contamination by providing quick, safe, effective on-the-go decontamination of masks and other noncritical PPE. It has been tested and proven effective to completely inactivate SARS-CoV-2 (COVID-19) in a published study conducted by Galveston National Lab (UTMB-Galveston), and it is proven to be non-toxic, non-irritating, non-sensitizing, safe on skin, and eco-friendly.

Launching this product was no easy task – Clyra set up contract manufacturing capable of delivering up to 1 million units per month, secured FDA registration, built a full-scale marketing campaign that is currently launching, and established partnerships with national distributors.

BioLargo also advanced its proprietary iodine technology to be used as an environmental disinfectant. Already, third-party studies were conducted that proved the product, derived from BioLargo’s CupriDyne® technology, achieving complete inactivation against SARS-CoV-2 in only 10 minutes.

This award is not the first time that BioLargo has been honored by Octane at their HTA event. In 2017, BioLargo received an Octane award for Horizontal Disruption because of the company’s diverse innovative life sciences technologies. The following year, BioLargo CEO Dennis P. Calvert was invited to be a judge for the 2018 HTA awards alongside decorated entrepreneur Shawn Dougherty (who is now Clyra Medical Technologies’ Chief Revenue Officer). We believe organizations like Octane, which is Orange County's premier tech incubator, are crucial in times like these, as they promote the advancement of critically important innovative technologies that help make people’s lives better.

On a Clyraguard-related note – we are anxious to update everyone on the advancement of Clyraguard sales, so keep an eye out for more Clyraguard news!

Wednesday, 2 September 2020

BioLargo’s CupriDyne Technology Shown Capable of Complete SARS-CoV-2 Inactivation in 10 Minutes

Westminster, CA – September 2, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today announced an important milestone in its ongoing efforts to bring to market a safe and effective antiviral disinfectant based on its patented CupriDyne® technology. In a third-party study conducted by researchers at the Galveston National Laboratory (GNL) at the University of Texas Medical Branch (UTMB), a modified CupriDyne formula was shown to cause complete inactivation of SARS-CoV-2 (the COVID-19 virus) in 10 minutes – roughly the same performance observed with highly concentrated bleach.

BioLargo had previously disclosed that its CupriDyne technology was proven capable of reducing SARS-CoV-2 titers by 99% after 30 minutes, with complete inactivation occurring after 60 minutes of CupriDyne exposure. Since that time, BioLargo scientists worked to modify the CupriDyne formula to achieve faster bacterial and viral inactivation in order to prepare to file for an EPA registration for a new disinfecting product (to be named) that is based on the CupriDyne technology. These new results indicate that those efforts were successful, and that the technology is now capable of total antiviral disinfection in 10 minutes against SARS-CoV-2.

BioLargo President & CEO Dennis P. Calvert commented, “We believe that the future is bright for our CupriDyne-based disinfectants. We intend to apply for registration with the EPA once product designs are finalized.  It is important to understand that we are achieving these extraordinary results at a significantly lower concentration than that of bleach in the same test protocol. We have retained a leading EPA consulting firm to lead us in the EPA registration process and intend to move ahead as soon as possible. These products are a great addition to our expanding portfolio.”

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About Galveston National Laboratory/UTMB

The Galveston National Laboratory (GNL) is a sophisticated high containment research facility that serves as a critically important resource in the global fight against infectious diseases. The GNL is located on the campus of the University of Texas Medical Branch and operates under the umbrella of UTMB’s Institute for Human Infections and Immunity.

Researchers at the GNL are internationally known for their expertise working with pathogens including Ebola and Marburg, emerging infectious diseases like MERS, and mosquito borne viruses like Zika and Chikungunya. The Galveston National Laboratory is home to research that is funded by NIAID, the U.S. Department of Defense, the U.S. Centers for Disease Control & Prevention and other federal agencies, as well as academic partners, private foundations, and the Biopharmaceutical industry.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

During the course of the stockholder presentation, BioLargo may make “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding future events or the future financial performance of the company that are subject to change. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.


Tuesday, 25 August 2020

BioLargo to Present at The LD 500 Virtual Conference

LOS ANGELES, CA / ACCESSWIRE / August 25, 2020 / BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today announced that it will be presenting at the LD 500 Investor Conference on Tuesday, September 1, 2020 at 8:00 AM PST / 11:00 AM EST. BioLargo President & CEO Dennis P. Calvert will be presenting to a live virtual audience of prospective investors.

A major focus of Mr. Calvert’s presentation will be Clyraguard Personal Protection Spray. BioLargo’s subsidiary Clyra Medical Technologies recently launched Clyraguard, a safe, effective, FDA-registered disinfectant for use on personal protection equipment (PPE) like facemasks. The company is currently ramping up distribution and sales of the new product through agreements with several contract manufacturers and a major national healthcare products distributor.

Mr. Calvert will also discuss the company’s per- and polyfluoroalkyl substance (PFAS) treatment technology, the BioLargo AEC, which is expected to begin its first pilots and commercial trials in late 2020 and early 2021. PFAS are a persistent and widespread class of contaminants of emerging concern globally due to their ability to cause serious health problems in humans and because of the difficulty with which they are removed from water. The BioLargo AEC has been proven capable of 99%+ PFAS removal from water in continuous flow and expects to be a low cost high efficiency solution for industry.

Register here: https://ld500.ldmicro.com/

"We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space.” stated Chris Lahiji, Founder of LD Micro.

The LD 500 will take place on September 1st through the 4th.

View BioLargo’s profile here: http://www.ldmicro.com/profile/BLGO


Profiles powered by LD Micro — News Compliments of Accesswire

 

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective against viruses and bacteria, and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.

What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.

The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

Name: Dennis P. Calvert

Phone: 888-400-2863

Email: dennis.calvert@biolargo.com

Source: BioLargo, Inc. via LD Micro